The purpose of this study is to establish the safety and feasibility of low dose LPS
administration to a small subset of humans in preparation for a larger USDA funded study
examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day
delivered as fish oil supplements) that significantly attenuates the inflammatory response
the investigators wish to examine the effects of an endotoxemia model for inducing
inflammation. Based on previous research, low dose LPS administration affects metabolism in
humans with only minimal clinical effects (such as "flu" like illness). Therefore, each of
the six subjects included in this small pilot study will receive a low dose of LPS and
placebo in order to learn more about the metabolic changes that occur during administration
and inflammation. The investigators hypothesis that LPS administration will elicit only
minimal clinical effects (such as "flu" like illness) when compared to placebo (saline--water
with the same amount of salt as in your blood).